The Precision Frontier: Revolutionising Head and Neck Cancer Management Through Theranostics, Liquid Biopsy, and AI-Powered Imaging

Abstract

Head and neck cancer (HNC) diagnostics are undergoing a transformative shift. Recent research published in Cancers highlights a paradigm shift in the comprehensive management of HNC, driven by precision oncology and disruptive technologies. AI-enhanced imaging and non-invasive biomolecular fingerprinting are redefining early detection, with tools like infrared spectroscopy and hyperspectral imaging delivering near-perfect accuracy and real-time surgical guidance. Liquid biopsy is emerging as a powerful surveillance modality, capable of detecting recurrence months before conventional imaging and offering prognostic insights via cell-free DNA analysis. Theranostic agents in nuclear medicine show promise for rare HNC subtypes, though broader molecular targets remain a challenge. These technologies may have utility for complex presentations such as proliferative verrucous leukoplakia (PVL)-associated oral squamous cell carcinoma (OSCC), which disproportionately affects women, and peri-implant OSCC, which is often misdiagnosed and requires aggressive intervention. Collectively, these innovations directly address long-standing challenges: early detection, accurate staging, treatment personalization, monitoring of minimal residual disease and timely cancer care—where diagnostics not only inform treatment but actively shape outcomes. This editorial underscores the urgency of integrating such tools into clinical pathways to improve survival and quality of life for HNC patients globally.